Dynavax Technologies (NASDAQ:DVAX) Hits New 12-Month High – Should You Buy?

Dynavax Technologies Co. (NASDAQ:DVAX)’s stock price hit a new 52-week high on Friday . The stock traded as high as $14.05 and last traded at $13.73, with a volume of 398164 shares. The stock had previously closed at $13.33.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on DVAX shares. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a report on Friday. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. HC Wainwright restated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research note on Friday. Finally, The Goldman Sachs Group downgraded Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th.

Dynavax Technologies Stock Performance

The firm has a market cap of $1.75 billion, a PE ratio of 74.06 and a beta of 1.32. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average price of $12.82 and a 200 day moving average price of $12.03.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. The business had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Institutional Trading of Dynavax Technologies

Several institutional investors and hedge funds have recently made changes to their positions in DVAX. GF Fund Management CO. LTD. acquired a new position in Dynavax Technologies in the fourth quarter valued at $35,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Dynavax Technologies by 37.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 420,325 shares of the biopharmaceutical company’s stock valued at $5,368,000 after buying an additional 113,872 shares in the last quarter. Woodline Partners LP grew its stake in shares of Dynavax Technologies by 2.2% in the fourth quarter. Woodline Partners LP now owns 794,475 shares of the biopharmaceutical company’s stock valued at $10,145,000 after buying an additional 17,156 shares in the last quarter. Squarepoint Ops LLC grew its stake in shares of Dynavax Technologies by 509.3% in the fourth quarter. Squarepoint Ops LLC now owns 124,807 shares of the biopharmaceutical company’s stock valued at $1,594,000 after buying an additional 104,325 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of Dynavax Technologies by 9.0% in the fourth quarter. Two Sigma Investments LP now owns 866,356 shares of the biopharmaceutical company’s stock valued at $11,063,000 after buying an additional 71,575 shares in the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.